RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

This study tested a single shot of an experimental RSV vaccine in 751 adults aged 50 and older in India, including those at higher risk for severe RSV. The goal was to see how well the vaccine boosts the immune system and whether it is safe. Results help determine if the vaccine …

This study looked at whether giving an RSV vaccine and a COVID-19 booster at the same time works as well as giving them separately. About 841 adults aged 50 and older took part. The goal was to see if the combination is safe and produces a strong immune response against both viru…

This study tested an experimental RSV vaccine in adults aged 18-49 who are at increased risk for RSV disease, comparing their immune response and safety to adults aged 60 and older. Around 1,459 participants received the vaccine. The goal was to see if the vaccine works as well i…

This study tested an experimental RSV vaccine from GSK in over 2,600 adults aged 60 and older, mostly in China and some overseas. The goal was to see if the vaccine produces a strong immune response and is safe. Researchers compared immune responses between Chinese and overseas p…

This study tested a single dose of a live-attenuated RSV vaccine given as nose drops to 88 children aged 4 months to 5 years. The goal was to check safety and whether the vaccine triggers an immune response. Participants included children who had and had not been infected with RS…

This study tested an experimental RSV vaccine in adults who had lung or kidney transplants, as well as in healthy older adults. Researchers wanted to see if one or two doses of the vaccine could safely boost the immune system's ability to fight RSV, a common and potentially serio…

This study tested a new medicine called TNM001 to see if it can prevent serious lung infections caused by RSV in high-risk babies under 1 year old. About 315 infants received either the medicine or a placebo and were followed for 9 months. The goal was to see if the antibody coul…

This study tested an injection called TNM001 to see if it can prevent serious lung infections caused by RSV in babies under one year old. Over 2,200 infants received either the injection or a placebo. The goal was to reduce the number of babies who get sick enough to need medical…

This study tested a medicine called nirsevimab in 33 Japanese infants under 1 year old who are at high risk for severe RSV infection due to heart or lung problems, weak immune systems, Down syndrome, or premature birth. The goal was to check safety and how the body responds to tw…

This study followed women who had received an RSV vaccine or a placebo in previous studies to see if it affected their later pregnancies. No new vaccine or treatment was given. The goal was to monitor pregnancy outcomes and safety in both mothers and babies. About 3,855 participa…